Company Overview and News

 
CNO (CNO) Down 2.7% Since Last Earnings Report: Can It Rebound?

2018-08-31 zacks
It has been about a month since the last earnings report for CNO Financial (CNO - Free Report) . Shares have lost about 2.7% in that time frame, underperforming the S&P 500.
CNO ADRO

 
CNO / CNO Financial Group, Inc. / BlackRock Inc. - null (Passive Investment)

2018-08-09 sec.gov
us12621e1038_080618.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) CNO FINANCIAL GROUP INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 12621E103 -------------------------------------------------------- (CUSIP Number) July 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cove
CNO

 
CNO / CNO Financial Group, Inc. / BlackRock Inc. - null (Passive Investment)

2018-08-09 sec.gov
us12621e1038_080618.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) CNO FINANCIAL GROUP INC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 12621E103 -------------------------------------------------------- (CUSIP Number) July 31, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cove
CNO

 
CNO / CNO Financial Group, Inc. 10-Q (Quarterly Report)

2018-08-03 sec.gov
Document Table of Contents
CNO

 
CNO Financial's (CNO) Q2 Earnings Miss Estimates, Up Y/Y

2018-08-02 zacks
CNO Financial Group, Inc.’s (CNO - Free Report) second-quarter 2018 adjusted earnings of 49 cents per share missed the Zacks Consensus Estimate of 51 cents. However, the bottom line improved 8.9% year over year, mainly driven by the Bankers Life segment.
CNO PGR ENR MTG BRO

1
7 Insurers Poised to Outperform in Q2 on Many Tailwinds

2018-07-12 zacks
The Finance sector is set to kick off its earnings season this week with major banks reporting quarterly results. Improving rate environment and tax cuts should continue to drive the sector’s performance. Per the Earnings Outlook, earnings for the sector are expected to increase 18.5% on 3.6% higher revenues. Insurers, an important component of the Finance sector, are shortly going to release their financial numbers.
UNM TMK TRV SLF PGR TMK CNO SLF ALL MFC MFC CB

45
I Recently Purchased This 10% Yielding BDC

2018-06-28 seekingalpha
TCPC is likely under-priced for the reasons discussed in this article, trading under book value, RSI of 38, and offering a well-supported 10% dividend yield.
AIY AINV CLA MCQ TCAP KAP MCV PFLT OSLE CGBD GLADO HTGZ KCAP GLAD ABDC MSCA TSLX TCCB CPTA TCCA MCC ARCC HCAPL GBDC FDUS MAIN TCC TCPC AIB HTGX NMFC HTGY CNO OCSI ARU OCSL MSCA.CL MCX HCAP SUNS HTGC

55
Unum (UNM) Raises Dividend by 13%, Okays $750M Share Buyback

2018-05-27 zacks
In a bid to enhance shareholder value, the board of directors of Unum Group (UNM - Free Report) recently hiked its quarterly dividend by 13% and approved a new $750-million share buyback program. The new dividend payout amounts to 24 cents per share compared with 23 cents paid earlier. The annualized dividend of $1.04 per share yields 2.7%, based on the closing price of $38.54 as of May 24. Shareholders are expected to be awarded with the meatier dividend during the third quarter of 2018.
UNM CNO DUKH LMT DUK CB

52
MetLife's Approves Share Buyback, Boosts Shareholders' Value

2018-05-23 zacks
MetLife, Inc.’s (MET - Free Report) board of directors has approved a new buyback authorization of common shares worth $1.5 billion. The recent announcement is in tandem with the company’s goal of returning $5 billion in capital to its shareholders in 2018. Last year, the company had announced a $2 billion repurchase under which it has bought back nearly $1.63 billion worth shares. Shares worth around $370 million still remains under its 2017 authorization.
CNO TOL MET CB

50
Chubb (CB) Enhances Shareholder Value With 3% Dividend Raise

2018-05-18 zacks
In a bid to share more profits with its shareholders, the board of directors of Chubb Limited (CB - Free Report) recently announced a 3% hike in quarterly dividend to 73 cents per share. Shareholders of record as of Jun 22 will have the meatier dividend in their pockets on Jul 13, 2018. The annualized dividend of $2.92 per share translates into a yield of 2.2% based on the closing price of $134.45 on May 17, 2018.
CNO CB Y

51
United Fire Rewards Investors With a 10.7% Dividend Hike

2018-05-18 zacks
In its concerted effort to share more profits with shareholders, the board of directors of United Fire Group Inc. has approved a quarterly dividend hike by 10.7%. The company will now pay a dividend of 31 cents per share, up from 28 cents payable Mar 22, 2018. Shares of the company gained 3.4% in the last couple of trading sessions, reflecting investor confidence in the stock.
CNO CB RLI Y

15
CNO Financial Rewards Investors With 11% Dividend Increase

2018-05-14 zacks
In its concerted efforts to enhance shareholder value, the board of directors of CNO Financial Group, Inc. (CNO - Free Report) recently hiked its quarterly dividend by 11%, translating into a payout of 10 cents, up from 9 cents paid in March 2018. However, shares of the company have slid 1.4% in the last couple of trading days. The annualized dividend of 40 cents yields 2.06%, based on the closing price of $19.
CNO KMPR KMPA MET RLI

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to CNO / CNO Financial Group, Inc. on message board site Silicon Investor.

Conseco Insurance (CNO) Conseco Insurance (CNO) Conseco Insurance (CNO) Conseco (CNO) Reborn Conseco (CNO) Reborn Conseco (CNO) Reborn
GTEC Grip Tecnologies---Any information?? Looks Good. GTEC Grip Tecnologies---Any information?? Looks Good. GTEC Grip Tecnologies---Any information?? Looks Good. Zhone Tecnologies Inc. Zhone Tecnologies Inc. Zhone Tecnologies Inc.
Tecnomatix Technologies Ltd. (TCNOF) - Any comments? Tecnomatix Technologies Ltd. (TCNOF) - Any comments? Tecnomatix Technologies Ltd. (TCNOF) - Any comments? SEER, Seer Tecnologies SEER, Seer Tecnologies SEER, Seer Tecnologies
TECNOL MED PRO (TCNL) TECNOL MED PRO (TCNL) TECNOL MED PRO (TCNL)
CUSIP: 12621E103